GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
Recruiting
Phase 3
Interventional Study
Subfertility
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 42
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 784 (estimated)
- Sponsor
- The University of Hong Kong · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
IVF
Inclusion criteria:
\- Women aged \<43 years at the time of IVF treatment
Exclusion criteria:
* Preimplantation genetic diagnosis treatment
* Use of donor oocytes or donor embryos
* Hydrosalpinx shown on pelvic scanning and not surgically treated
* Women at risk of OHSS
FET
Inclusion crite…
Contacts